Lung cancer: partnership between BMS France and Sivan to deploy the Moovcar remote monitoring software

Bristol-Myers Squibb (BMS) France and the company Sivan announced on March 16 an exclusive partnership to "support the deployment" of the remote monitoring software Moovcare to hospitals and health professionals involved in the treatment of lung cancer in France .

The Moovcare lung software, designed by Sivan, could be the first telemonitoring tool reimbursed under common law in France, we recall. In April 2019, the class I medical device marked CE obtained a favorable opinion for its reimbursement from the National Commission for the Evaluation of Medical Devices and Health Technologies (Cnedimts) of the High Authority for Health (HAS).

Cnedimts notably relied on the phase III comparative trial piloted by the tool’s designer, Fabrice Denis from the Jean-Bernard du Mans Interregional Cancer Institute, presented at the congress of the American Society of Clinical Oncology (ASCO) in 2016 to assess the solution.

“The reimbursement is still being negotiated with the Economic Committee for Health Products (CEPS) to determine a viable price that suits us,” Ayala Bliah, Deputy General Manager of Sivan, told TICpharma. “The solution is now freely available to hospitals and patients,” she said.

As part of the exclusive one-year partnership with BMS France, the French subsidiary of the American group undertakes to “promote Moovcare to all hospitals and healthcare professionals concerned with the care of cancer patients. lung, “Dana Vigier, executive director” oncology “of BMS France, told TICpharma.

“We started from the principle that today there is a non-drug solution that prolongs the lives of patients with lung cancer, it has proven its robustness and its effectiveness scientifically and we wanted to bring our expertise in immuno-oncology to help Sivan deploy it. Our idea is to allow lung cancer to be a chronic disease in the long run, “she said.

For this, BMS will mobilize its field collaborators who will be responsible for presenting the Sivan solution to healthcare professionals and hospitals throughout France and putting them in contact with society, if they wish to use the Moovcare software to remote monitor their patients. sick.

“BMS France cannot, legally, distribute Moovcare, nor organize its implementation. If a hospital is interested, they put us in contact with them and we take care of the training in the tool and its installation”, specified Ayala Bliah at TICpharma.

Effectiveness of digital therapeutic solutions in oncology

Moovcare is a reporting application adapted to post-surgical follow-up, post-induction chemotherapy, to patients who are undergoing treatment with maintenance chemotherapy or immunotherapy, we recall.

Concretely, each week, the software sends an email to the patient inviting him to answer a questionnaire (on mobile, computer or tablet) of 12 items. An algorithm then analyzes the responses taking into account the responses from previous weeks and, if a risk of recurrence or complications is detected, an alert is sent to the referring specialist doctor.

The solution thus favors an early detection of relapses and allows the doctor to react more quickly and to adapt the treatment to the clinical evolution of the patient in real time. It has shown a 7-month increase in overall survival for patients benefiting from the solution.

“We are witnessing a digital revolution, BMS is a pioneer in immunotherapy which he made an extraordinary bet in 2011 and it is with this in mind that we have chosen to partner with Sivan to extend the lives of patients with lung cancer” , explained Dana Vigier.

“In France, this partnership is immediate to allow each patient to benefit. Our parent company, BMS USA, recently announced a partnership with the company Voluntis to create digital therapeutic solutions for patients with other cancers, “she said.

“Today, with the Covid-19 crisis, we are seeing the value of an application like Moovcare for lung cancer patients who can no longer travel to hospitals,” said Ayala Bliah.

A look at the news shared by Dana Viguier who insists on “the channel” offered by the software solution to “allow patients and their doctors to keep in touch and sort through information requiring or not a trip to the hospital”.

Currently, “a hundred patients” use the Moovcare application, counted the deputy director general of Sivan, who hopes “6,000 patient users within three years”.

In the meantime, Sivan “is conducting several studies to extend Moovcare to other cancers, with the Institut Curie in particular and in the United States, where it has opened an office” and is preparing to “soon expand commercially in Germany, primarily “but also in the United States and the United Kingdom, told TICpharma Ayala Bliah.

Wassinia Zirar
Wassinia.Zirar@apmnews.com